What Happened?
Cambridge, MA-based Cyteir-Therapeutics Appointed Markus Renschler as President and Chief Executive Officer
About the Company
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
About the Person
Markus Renschler is President and Chief Executive Officer at Cyteir Therapeutics. Previously, Markus held various senior HR leadership roles in the industry.
Info Source
News
Short Profile